ABIVAX Société Anonyme Gestione

Gestione criteri di controllo 2/4

ABIVAX Société Anonyme Il CEO è Marc M. de Garidel, nominato in May2023, e ha un mandato di 1.42 anni. la retribuzione annua totale è € 793.97K, composta da 45.3% di stipendio e 54.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.06% delle azioni della società, per un valore di € 371.93K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 3.2 anni.

Informazioni chiave

Marc M. de Garidel

Amministratore delegato

€794.0k

Compenso totale

Percentuale dello stipendio del CEO	45.3%
Mandato del CEO	1.4yrs
Proprietà del CEO	0.06%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	3.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued

Dec 11

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

Jun 06

A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary

Dec 31

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Marc M. de Garidel rispetto agli utili di ABIVAX Société Anonyme?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-€177m
Mar 31 2024	n/a	n/a	-€163m
Dec 31 2023	€794k	€359k	-€148m

Compensazione vs Mercato: La retribuzione totale di Marc M. ($USD 862.26K ) è circa la media per le aziende di dimensioni simili nel mercato French ($USD 948.39K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Marc M. con le performance aziendali.

AMMINISTRATORE DELEGATO

Marc M. de Garidel (66 yo)

1.4yrs

Mandato

€793,971

Compensazione

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He serves as CEO at ABIVAX Société Anonyme since May 5, 2023 amd serves as its Director. He had been its Interim Chair...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% € 371.9k
Philippe Pouletty	Founder & Director	no data	€35.00k	0.43% € 2.7m
Didier Blondel	EVP, CFO & Board Secretary	7.8yrs	Nessun dato	0.00059% € 3.6k
Didier Scherrer	Chief Scientific Officer	1.2yrs	Nessun dato	0.057% € 348.8k
Patrick Malloy	Senior Vice President of Investor Relations	1.2yrs	Nessun dato	Nessun dato
Ida Hatoum	Chief People & Compliance Officer	1.3yrs	Nessun dato	Nessun dato
Pierre Courteille	Chief Business Officer	no data	Nessun dato	0% € 0
Jerome Denis	Executive Vice President of Process Development & Manufacturing	1.1yrs	Nessun dato	Nessun dato
Michael Ferguson	Chief Commercial Officer	1.5yrs	Nessun dato	Nessun dato
Ana Sharma	VP & Global Head of Quality	less than a year	Nessun dato	Nessun dato
Hema Keshava	Senior Vice President of Finance	no data	Nessun dato	Nessun dato
Chris Rabbat	VP & Global Head of Medical Affairs	no data	Nessun dato	Nessun dato

1.3yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di ABVX non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% € 371.9k
Philippe Pouletty	Founder & Director	10.8yrs	€35.00k	0.43% € 2.7m
Sylvie Gregoire	Chair of the Board	less than a year	Nessun dato	Nessun dato
Christian Trepo	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Lawrence Stanberry	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Troy Ignelzi	Independent Director	1.3yrs	€44.33k	Nessun dato
Christoph Huber	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Claude Bertrand	Member of Scientific Advisory Board	5yrs	€4.94k	Nessun dato
Luc Teyton	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
June Lee	Independent Director	1.3yrs	€35.24k	Nessun dato
Corinna Bonsen-Thomas	Independent Non-Executive Director	7.3yrs	€135.16k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	6.3yrs	Nessun dato	Nessun dato

3.2yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABVX sono considerati esperti (durata media dell'incarico 3.2 anni).

ABIVAX Société Anonyme Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Insufficient new directors

Recent updates

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Does ABIVAX Société Anonyme (EPA:ABVX) Have A Healthy Balance Sheet?

Price target decreased by 18% to €29.18

Consensus revenue estimates increase by 18%

Consensus revenue estimates increase by 69%

Price target increased by 7.1% to €38.28

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?

Consensus revenue estimates increase by 22%

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 29%

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

New major risk - Share price stability

Price target decreased by 16% to €30.33

New minor risk - Share price stability

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

New major risk - Revenue and earnings growth

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

No longer forecast to breakeven

Price target decreased by 16% to €41.25

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

No longer forecast to breakeven

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Price target increased to €49.30

Insufficient new directors

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Price target increased to €49.30

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Price target decreased to €45.50

Price target decreased to €56.80

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

Forecast breakeven date moved forward to 2022

Insufficient new directors

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Consensus forecasts updated

Consensus forecasts updated

An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Price target increased to €63.56

No longer forecast to breakeven

Price target increased to €58.63

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Price target decreased to €35.95

New 90-day low: €21.00

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary

New 90-day high: €28.95

Price target raised to €38.97

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

New 90-day high: €21.85